Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT and Defactinib in Advanced Pancreas Adenocarcinoma
NCT04331041Phase 2Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Aug 2021
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of defactinib in pancreatic adenocarcinoma (PDAC), sponsored by Washington University School of Medicine. Started Aug 2021; status: active, not recruiting.
02
Drugs
defactinib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04331041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04331041.